Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.

You may also be interested in...



Phase II Diabetes Data Heighten Incyte’s Partnership Appeal

Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.

Phase II Diabetes Data Heighten Incyte’s Partnership Appeal

Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.

JAKs Are Better? Oral Inhibitors Could Beat Injected Biologics In RA

Buzz over data from trials with Janus-associated kinase inhibitors at the American College of Rheumatology meeting is heating up the debate over whether the class will ultimately beat injected biologics in rheumatoid arthritis

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel